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Expression of NOTCH3 exon 16 
differentiates Diffuse Large B-cell 
Lymphoma into molecular subtypes 
and is associated with prognosis
Ditte Starberg Jespersen1, Anna A. Schönherz1,4, Hanne Due1, Martin Bøgsted1,3,4, 
Teis Esben Sondergaard2 & Karen Dybkær1,3,4
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with diverse clinical presentation and 
outcome. Bio-clinical prognostic models including oncogene expression and cell-of-origin phenotyping 
has been developed, however, approximately 30% of all patients still die from their disease, illustrating 
the need for additional prognostic biomarkers associating oncogenesis and phenotypic subclasses. 
Hence, we tested if alternative splice variations have biomarker potential. Initial alternative splicing 
analysis of human exon array from clinical DLBCL samples identified candidate genes. Experimental 
validation by ddPCR was performed in a DLBCL cohort classified into ABC/GCB subclasses, B-cell 
associated gene signatures (BAGS: naive, centroblast, centrocyte, memory, and plasmablast), 
and vincristine resistant gene signatures. Prognostic potential was assessed for aberrantly spliced 
transcripts. Thus, NOTCH3 was identified as alternatively spliced, with differential exon 16 depletion  
(−exon 16) between differentiation associated BAGS subtypes. Predicted vincristine resistant patients 
of the GCB subclass had significantly downregulated NOTCH3 −exon 16 transcript expression and 
tended to display adverse overall survival for R-CHOP treated patients. In conclusion, we have identified 
a specific alternatively spliced NOTCH3 event that differentiate molecular subtypes of DLBCL and 
display prognostic and predictive biomarker potential in GCB DLBCL.
Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoid neoplasm among adults, accounting for 
30% to 40% of all Non-Hodgkin’s lymphomas1. The immuno-chemotherapeutic regimen rituximab, cyclophos-
phamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard treatment for primary diagnosed 
DLBCL, however, 30–40% of DLBCL patients eventually die from relapse or refractory disease2–4. DLBCL is a 
heterogeneous disease displaying diverse clinical presentation, outcome, cellular morphology, and pathogenic 
mechansism1,5. Hence, there is a need to identify and understand determinants of DLBCL heterogeneity to obtain 
better risk stratification of DLBCL patients6.
Based on gene expression profiling (GEP) DLBCL patients are classified into molecular subclasses with inher-
ent prognostic impact: e.g. the ABC/GCB, the B-cell associated gene signature (BAGS) or the resistance gene 
signature (REGS) classification systems7–9.
Most widely used is the cell-of-origin classification system ABC/GCB consisting of activated B-cell (ABC) 
DLBCL, germinal center B-cell (GCB) DLBCL, and unclassified (UC) DLBCL, which recently have been included 
in the WHO guidelines10. The ABC/GCB subclasses differ in pathogenesis and survival outcome with ABC clas-
sified patients having an impaired 5-year survival rate compared to those classified as GCB when treated with 
R-CHOP7.
The BAGS classification is a refined cell-of-origin classification system where primary tumors at time of 
diagnosis are associated with normal B-cell subset phenotypes and classified into naive, centroblast, centro-
cyte, memory, and plasmablast B-cell subtypes providing additional prognostic information to molecular ABC/
GCB subclasses. The most distinct prognostic impact of BAGS is observed within the GCB subclass, where the 
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GCB-centroblast subtype display adverse survival outcome compared to the GCB-centrocyte subtype8. In addi-
tion, different activated signalling pathways, genetic profiles, and responses to chemotherapeutic drugs used in 
treatment of DLBCL is observed for the BAGS subtypes8,9.
The response of DLBCL patients to chemotherapeutic drugs of R-CHOP can be predicted by the REGS clas-
sification system, which is based on systematic in vitro dose response drug screens of B-cell cancer cell lines 
with cyclophosphamide, doxorubicin, or vincristine. Baseline GEP of untreated cell lines was combined with the 
degree of dose dependent growth inhibition after drug exposure. REGS allows assignment of a drug resistance 
probability to individual DLBCL patients, providing prognostic risk stratification of DLBCL patients9.
These molecular classifications have increased the biological understanding of DLBCL, however, it has 
recently been suggested that alternative splicing events and alternative exon usage have a significant role in the 
pathogenesis of DLBCL6.
The majority of human genes express alternatively spliced mRNA transcripts, contributing to proteomic diver-
sity as well as tissue- and cell specific gene expression11,12. Alteration in the splice mechanism can contribute to 
malignant transformation, cancer progression, and metastasis13–15. Ratio modifications of normally occurring 
transcript variants, specific splice events, and cancer specific exon inclusion/exclusion are potential novel bio-
markers and drug targets in cancer16,17. Previous studies have shown that expression of specific splicing events 
differs between prognostic subtypes of DLBCL and may hold biomarker potential6,18–20.
Increasing evidence has emerged that deregulated Notch signalling play a role in cancer progression. 
Mutations in NOTCH1 and NOTCH2 have been linked to haematological malignancies in several studies, 
including DLBCL6,21–27. Notch protein receptors (Notch1–4) differ structurally in their intra- and extracellular 
domain as they each participate specifically in conserved signalling pathways that regulate differentiation, cell 
cycle, proliferation, progression, and maintenance in development of several tissues and cell types, including lym-
phoid cells and self-renewal of hematopoietic stem cells21,27–30. In hematopoietic progenitor cells, Notch signalling 
promotes T-cell lineage commitment while inhibiting the B-cell lineage commitment31. Although, knowledge of 
the NOTCH genes involvement have increased in haematological malignancies, findings have recurrently been 
focused at the DNA level26. Since alternative splicing is a tightly regulated mechanism, altered splicing of NOTCH 
genes may affect B-cell lineage development and cause pathogenic transformations. Specific altered alternatively 
spliced events in NOTCH genes could be useful as molecular biomarkers in order to improve risk stratification 
of DLBCL patients.
In this study, we identified the alternative transcript of NOTCH3 missing exon 16 (−exon 16) (Fig. 1, 
ENST00000601011.1) by human exon expression profiles and subsequently experimentally validated the expres-
sion of alternative splicing events using droplet digital PCR (ddPCR) in a primary DLBCL cohort (n = 75). 
NOTCH3 excluding exon 16 was investigated for association with the DLBCL subclasses ABC/GCB, BAGS, and 
REGS vincristine subtypes documenting prognostic and predictive biomarker potential.
Results
Clinical characteristics. Baseline characteristics of the retrospective clinical cohort of 75 DLBCL patients 
are presented in Table 1. Mean age of the patients was 65 years (range 31–85). For identification of alternatively 
spliced genes, 37 primary DLBCL patients were analysed using HuEx. 1.0 array (Table 1). For subtype classifica-
tion all 75 patients were analysed by HG-U133 Plus 2.0, including the 37 patients used in identification of can-
didate gene. For prognostic association, 60 R-CHOP treated patients with a median follow-up time of 4.6 years 
were analysed (Table 1).
Identification of candidate genes using exon arrays. Alternatively spliced genes associated with 
molecular subtypes of DLBCL were identified by the alternative splice analysis of variance (asANOVA) in 37 clin-
ical DLBCL samples analysed by human exon arrays. Class comparison of ABC/GCB and BAGS classified patients 
listed 882 and 3442 candidate genes, respectively. Since the pronounced prognostic impact of the BAGS classifi-
cation is present between the GCB-centroblast and GCB-centrocyte subtype8, class comparison was performed 
Figure 1. NOTCH3 transcripts and structural overview of the corresponding Notch3 protein. The upper panel 
shows the canonical NOTCH3 transcript (red) and the alternatively spliced transcript (green) missing exon 
16 and 24–33. The lower panel presents the structure of the canonical Notch3 protein, which is a heterodimer 
consisting of a ligand-binding extracellular domain and an intracellular domain mediating target gene 
transcription. Exon 16 of the canonical transcript (box) codes for three EGF-like domains, which are absent 
in the alternatively spliced transcript. EGF: Epidermal growth factor, LNR: LIN12-NOTCH repeats, HDD: 
heterodimerization domains, NRR: negative regulatory region, TM: transmembrane domain, RAM: (RBPJ) 
association molecule, ANK: ankyrin repeats, PEST: proline (P), glutamine (E), serine (S), threonine (T) rich 
region.
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specifically for these two subtypes resulting in 193 candidate genes detected (Table 2). Selection of alternatively 
spliced candidate genes was based on an adjusted p < 0.05, visual inspection of exon expression across genes, 
and literature research. Thus, NOTCH3 emerged as the best candidate since exon 16 was alternatively spliced 
between the BAGS subtype centroblast vs. naive, plasmablast, memory, and centrocyte. Furthermore, exon 16 
was alternatively spliced between the GCB-centroblast and GCB-centrocyte subtypes (Table 2). No difference in 
NOTCH3 exon expression was observed between ABC and GCB subclasses (Fig. 2A). Within the BAGS subtypes, 
however, centroblasts displayed lower exon 16 expression compared to the other subtypes (Fig. 2B), and when 
restricting the analysis to GCB-centroblast and GCB-centrocyte subtypes, loss of exon 16 was observed for the 
former (Fig. 2C), suggesting subtype specific exon 16 depletion in the centroblast subtype. Exon expression across 
the NOTCH3 gene are provided in Supplementary Figs 1–3.
To substantiate whether total gene expression of NOTCH3 could differentiate centroblasts from the other 
BAGS subtypes in DLBCL, all HuEx. 1.0 probe set expressions specific for each exons in NOTCH3 were extracted 
Characteristics
DLBCL HuEx. 1.0 cohort* n (%)
DLBCL 
cohort** n (%)
DLBCL R-CHOP 
treated cohort n (%)
For identification of alternatively 
spliced genes
For subtype 
association
For prognostic 
assessment
No. of patients 37 75 60
Gender
Female 17 (46) 32 (43) 23 (38)
Male 20 (54) 43 (57) 37 (62)
Age, Years
Mean 63 65 65
Range 31–81 31–85 31–85
IPI score
0–1 11 (30) 18 (24) 15 (25)
2–3 17 (46) 37 (49) 31 (52)
4–5 7 (19) 14 (19) 11 (18)
NA 2 (5) 6 (8) 3 (5)
ABC/GCB
ABC 17 (46) 33 (44) 26 (43)
GCB 18 (48) 33 (44) 26 (43)
UC 2 (5) 9 (12) 8 (13)
BAGS
Naive 3 (8) 9 (12) 5 (8)
Centroblast 8 (22) 13 (17) 11 (18)
Centrocyte 14 (38) 32 (43) 25 (42)
Memory 5 (13) 11 (15) 10 (17)
Plasmablast 7 (19) 10 (13) 9 (15)
REGS vin
Sensitive 17 (46) 29 (39) 23 (38.3)
Intermediate 10 (27) 18 (24) 11 (18.3)
Resistant 10 (27) 28 (37) 26 (43.3)
Table 1. Patient characteristics of clinical DLBCL cohorts. IPI: International Prognostic Index, NA: not 
available, ABC: activated B-cells, GCB: germinal center B-cells, UC: unclassified, BAGS: B-cell associated gene 
signatures, REGS: resistance gene signatures, vin: vincristine. *Analyzed using HuEx. 1.0 array, **Subtype 
classification based on HG-U133 array.
ABC/GCB (no. genes) BAGS (no. genes)
GCB-CB/GCB-CC 
(no. genes) Inclusion criteria
882 3442 193 asANOVA (FDR corrected p < 0.05)
50 50 50 Top 50
2 (FOXP1, NLRP4) 2 (NOTCH3, NID2)
4 (NOTCH3, LMO2, 
NLRP4, PRDM15)
Visual inspection of exon expression across 
genes (selected genes after visual inspection)*
FOXP1, NLRP4, NOTCH3, NID2, LMO2, PRDM15 Literature research
NOTCH3 Selected alternatively spliced gene candidate
Table 2. Identification of alternatively spliced candidate gene. *Genes in bold are represented in more than 
one list. ABC: activated B-cells, GCB: germinal center B-cells, BAGS: B-cell associated gene signature, CB: 
centroblast, CC: centrocyte, asANOVA: alternative splice analysis of variance, FDR: False discovery rate.
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and summarized to a mean gene expression of NOTCH3, showing no significant difference between centro-
blast and centrocyte subtypes at gene level (Supplementary Fig. 4A). Thus, the NOTCH3 biomarker poten-
tial for distinguishing centroblast and centrocyte subtypes was observed only at exon level and not gene level. 
However, NOTCH3 gene expression differentiated the centroblast subtype from plasmablast subtypes (p = 0.027, 
Supplementary Fig. 4A). Similar when analysing healthy B-cells subset from tonsils association to NOTCH3 gene 
expression, no significance was found between the B-cell subsets (Supplementary Fig. 4B). However, when com-
paring DLBCL BAGS subtypes with healthy B-cell subsets a general lower expression of the NOTCH3 gene were 
observed in all of the healthy subsets from tonsils (Supplementary Fig. 4A,B).
NOTCH3 −exon 16 transcript expression differentiates molecular subtypes of DLBCL by 
ddPCR. To analyse, if NOTCH3 −exon 16 was able to differentiate molecular subtypes of DLBCL, the expres-
sion were quantified in 75 clinical DLBCL samples using ddPCR and subtype associations were performed using 
unpaired t-test. Transcript expression of NOTCH3 −exon 16 did not reveal significant differences between ABC 
and GCB subclasses (Fig. 3A).
However, different expression patterns of the NOTCH3 −exon 16 transcript were observed between BAGS 
subtypes, displaying significant difference between centroblasts and centrocytes (p = 0.02, Fig. 3B), centroblasts 
and plasmablasts, and centrocytes and plasmablasts (p = 0.01, p = 0.04, respectively, Supplementary Fig. 5A). 
For BAGS subtype testing restricted to the GCB and ABC subclass, differential exon expression was observed 
within the GCB subclass alone (Fig. 3C, Supplementary Fig. 5B). In the GCB subclass, GCB-centroblast clas-
sified patients displayed lower NOTCH3 −exon 16 transcript expression compared to those classified as 
GCB-centrocyte (p = 0.02, Fig. 3C), an observation in accordance with exon array based results from Fig. 2C.
Subtype specific exon usage of NOTCH3 exon 16 in molecular BAGS subtypes of DLBCL. 
Alternative exon expression of the NOTCH3 −exon 16 transcript were observed between BAGS subtypes, thus 
in order to investigate if the usage of NOTCH3 +/−exon 16 transcripts was subtype specific, ratios of NOTCH3 
Figure 2. Exon specific expression of NOTCH3. RMA normalized exon specific expression assessed by HuEx. 
1.0 array with focus on exon 15–18 of the NOTCH3 gene, as an alternatively spliced transcript missing exon 16 
was identified, in DLBCL patients classified as (A) ABC/GCB subclasses, (B) BAGS subtypes, and (C) GCB-
centroblast and GCB-centrocyte. Data points represent the mean probe set expression in the respective exons 
for each molecular subtype of DLBCL. ABC: activated B-cells, GCB: germinal center B-cells, CB: centroblast, 
CC: centrocyte, M: memory, and PB: plasmablast. RMA: Robust Multichip Average normalized.
www.nature.com/scientificreports/
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+/−exon 16 transcripts were assessed as the slope of the linear regression curve (Supplementary Table 1), while 
variation in expression was explained by correlation analyses (Fig. 4). In general, the NOTCH3 −exon 16 tran-
script was expressed at a much lower level than NOTCH3 +exon 16 as illustrated by slopes above 10 for all anal-
yses (Supplementary Table 1). The naive subtype differed in slope and correlation coefficient (r) when compared 
to other BAGS subtypes, suggesting subtype specific exon usage and expression patterns (Fig. 4A, Supplementary 
Tables 1 and 2). In addition, the centrocyte and centroblast subtypes of the entire cohort and restricted to the 
GCB subclass had different NOTCH3 +/−exon 16 ratios (Supplementary Table 1, slope for centroblast: 58.1, 
centrocyte: 25.18, GCB-centroblast: 55.89, and GCB-centrocyte: 25.58), further supporting subtype specific 
expression (Fig. 4B–D,F). The centrocyte subtype had significantly lower correlation coefficient compared to the 
centroblast subtype, showing more variation in transcript expression within this specific subtype (p = 0.0046, 
Fig. 4B,D, Supplementary Table 2). For memory and plasmablast subtypes, high correlation coefficients and sim-
ilar expression pattern of NOTCH3 +/−exon 16 were observed (Fig. 4G–J). Varying exon 16 usage in NOTCH3 
and expression patterns between BAGS subtype, suggest that NOTCH3 exon 16 is expressed differently depend-
ing on which differentiation step the malignant B-cells are derived from.
High expression of the NOTCH3 −exon 16 transcript is associated with vincristine sensitivity. 
Each individual clinical sample was assigned a drug-specific response probability to vincristine, one of the cor-
nerstones of R-CHOP, using the REGS classifier, dividing the entire cohort and ABC/GCB subclasses into three 
groups of vincristine sensitive, intermediate, and resistant (Fig. 5A–C). Association between the NOTCH3 −exon 
16 transcript and vincristine response subtypes was observed within the GCB subclass (Fig. 5C). The NOTCH3 
−exon 16 transcript was more highly expressed in DLBCL patients predicted to be vincristine sensitive compared to 
those classified as vincristine resistant (p = 0.001, Fig. 5C). The vincristine sensitive group of GCB classified patients 
mainly consisted of GCB-centrocytes, which previously has been predicted to be more sensitive to vincristine than 
GCB-centroblasts8. Additionally, the vincristine resistant group of GCB classified patients had significantly lower 
expression of the NOTCH3 −exon 16 transcript compared to the intermediate group (p = 0.006, Fig. 5C).
Expression of NOTCH3 splice event trends to associate with prognosis in DLBCL. To evalu-
ate the prognostic potential of NOTCH3 −exon 16 transcript expression, survival analyses were performed in 
R-CHOP treated DLBCL patients (n = 60) (Fig. 5D–F). Patients were separated into two equally large groups 
according to low and high expression of the NOTCH3 −exon 16 transcript. Differences between Kaplan-Meier 
estimates of survival probabilities for each group were determined using a log-rank test. Expression levels of 
NOTCH3 −exon 16 transcript were borderline associated with OS within the GCB subclass (Fig. 5F), whereas 
no prognostic stratification was obtained in the entire DLBCL cohort or in ABC classified patients (Fig. 5D,E). 
Further investigation of the NOTCH3 −exon 16 transcript as an independent prognostic biomarker was not pur-
sued given the low sample size, yet the results suggests that expression of the NOTCH3 −exon 16 transcript has 
prognostic potential within GCB DLBCL.
NOTCH3 −exon 16 transcript expression in healthy lymph node tissue. NOTCH3 −exon 16 tran-
script expression was able to differentiate DLBCL into molecular subtypes, however, when comparing the expression 
in healthy lymph nodes (n = 6) to the entire DLBCL cohort, the NOTCH3 −exon 16 transcript failed to discriminate 
DLBCL from healthy controls (Fig. 6A). In addition, expression of the centroblast, GCB-centroblast, and GCB vin-
cristine resistant subtype of DLBCL was significantly downregulated compared to healthy lymph nodes (p = 0.004, 
p = 0.001, p = 0.0004, respectively, Fig. 6B–D), contradictory to the higher NOTCH3 gene expression observed in 
DLBCL BAGS subtypes compared to healthy B-cell subsets from tonsils at Supplementary Fig. 4A,B. However, the 
difference in NOTCH3 expression between healthy lymph nodes and the B-cell subsets was most likely affected by 
the different compositions of cells in the samples, since healthy lymph nodes consist of a mixture of cells, while the 
sorted healthy B-cell subsets consist of pure B-cells. Results indicate that the biomarker potential of the NOTCH3 
−exon 16 transcript rely within stratification of DLBCL, and not as a diagnostic marker.
Figure 3. Association of NOTCH3 −exon 16 with molecular subtypes of DLBCL. Subtype association of 
NOTCH3 −exon 16 expression determined by ddPCR with (A) ABC and GBC classified DLBCL patients, (B) 
patients classified as centroblast and centrocytes, and (C) the centroblast and centrocyte subtype of GCB classified 
patients. ABC: activated B-cells, GCB: germinal center B-cells, CB: centroblast, CC: centrocyte. Median Whiskers 
boxplots were created with dots representing raw data points from maximum to minimum. *p < 0.05.
www.nature.com/scientificreports/
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Discussion
In this study, we identified NOTCH3 as an alternatively spliced gene and subsequently experimentally validated 
the biomarker potential in a primary DLBCL cohort. Patients were classified into molecular subtypes of DLBCL 
using GEP-based classifications, ABC/GCB and BAGS, which based on the B-cell degree of differentiation risk 
stratify DLBCL patients7,8 and REGS predicting vincristine response9. The alternative transcript of NOTCH3 
Figure 4. Correlation analysis of NOTCH3 +/−exon 16 expression in BAGS subtypes of all DLBCL patients 
and within ABC/GCB subclasses. Correlation of NOTCH3 +/−exon 16 in BAGS subtypes and BAGS within 
ABC/GCB subclasses, evaluated by Pearson’s correlation coefficient (r). Dashed lines represent the 95% 
confidence bands of the best-fit curve found by linear regression analyses. ABC: activated B-cells, GCB: 
germinal center B-cells, r: Pearson’s correlation coefficient.
www.nature.com/scientificreports/
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Figure 5. The NOTCH3 −exon 16 transcript associate with REGS vincristine subtypes and trends to associate 
with OS. Subtype association with NOTCH3 −exon 16 expression in vincristine response subtypes of (A) 
the entire cohort and (B,C) within ABC and GCB classified patients. Pink and green data points represent 
centrocyte and centroblast classified patients, respectively. (D) Kaplan-Meier estimates of NOTCH3 −exon 16 
expression and OS in the entire DLBCL cohort (n = 60), (E) within the ABC subclass (n = 26), and (F) within 
the GCB subclass (n = 26). **p < 0.001. ABC: activated B-cells, GCB: germinal B-cells.
Figure 6. The NOTCH3 −exon 16 transcript expression in DLBCL compared to healthy lymph node controls. 
ddPCR quantified expression of the NOTCH3 −exon 16 transcript in healthy lymph node controls compared 
to (A) the entire DLBCL cohort, (B) BAGS subtypes, (C) BAGS subtypes within GCB, and (D) vincristine 
response in GCB classified patients. CB: centroblast, CC: centrocyte, HL: healthy lymph nodes, M: memory, N: 
naive, PB: plasmablast. **p < 0.001, ***p < 0.0001.
www.nature.com/scientificreports/
8SCientifiC RepoRts |           (2019) 9:335  | DOI:10.1038/s41598-018-36680-x
missing exon 16 was selected as experimental candidate, since it displayed differential exon expression between 
BAGS subtypes and GCB-centroblast vs. GCB-centrocytes in the HuEx. 1.0 array analysis. Interestingly, when 
summarizing HuEx. 1.0 probe-expressions to a total NOTCH3 gene expression level, no differential expression 
was observed for ABC/GCB and most BAGS subtypes, contradictory to the result observed at exon level. Only the 
plasmablast showed significantly higher expression than centroblast at gene level. The loss of information at gene 
level is in agreement with Leivonen, et al.6, reporting that alternatively spliced events are able to discriminate the 
molecular ABC/GCB subclasses of DLBCL and have prognostic impact that is not seen at gene level.
Additionally, healthy B-cells subsets from tonsil tissue were analysed for the total NOTCH3 gene expression 
using HuEx. 1.0 arrays, showing no significant difference between healthy subsets. However, the expression of 
NOTCH3 for each healthy B-cell subset were higher compared to DLBCL subtypes. Especially, the DLBCL plas-
mablast had upregulated NOTCH3 gene expression compared to the healthy plasmablast subtype, which is in 
accordance with Delgado-Calle, et al.32 reporting that over-expression of NOTCH3 is observed in neoplastic 
plasma cells in Multiple Myeloma.
Despite a shift in detection platform, differential expression between BAGS subtypes and GCB-centroblast vs. 
GCB-centrocyte was confirmed using ddPCR, in which centroblasts displayed lower levels of the NOTCH3 −
exon 16 transcript compared to centrocytes in accordance with exon array based findings. Differential expression 
of the NOTCH3 −exon 16 transcript in molecular subtypes was predominantly observed in the GCB subclass, 
implying that the NOTCH3 −exon 16 transcript expression is cell specific and may contribute to the heteroge-
neity of DLBCL. I addition, a significantly lower expression of the NOTCH3 −exon 16 transcript was observed 
in GCB patients classified as vincristine resistant by the REGS classifier, supporting the BAGS classification of 
DLBCL, which predicted centroblasts to be more vincristine resistant8,9. The role of altered alternative splicing in 
drug resistance of other malignancies have been demonstrated previously; cells expressing an alternative BRAF 
transcript lacking exon 4–8 showed increased resistance towards vemurafenib in melanomas33 and a truncated 
CD19 isoform without the segment encoded by exon 2 resulted in invisibility to CART-19 immunotherapy34. 
Implication of NOTCH3 in chemoresistance have been reported in breast and ovarian cancer35–37, however, to 
our knowledge, the role of the NOTCH3 −exon 16 transcript in vincristine response has not been described 
previously, yet current data support that NOTCH3 −exon 16 splice events have an effect on the vincristine resist-
ance mechanism in DLBCL. However, to confirm link between alternative splicing of NOTCH3 and vincristine 
response, functional assays have to be performed.
The alternative splicing mechanism is tightly regulated in a tissue- and cell specific manner, where lymphoid 
tissue is documented to have one of the greatest enriched tissue-specific splicing38,39. Consequently, studies 
confirm that cell type dependent altered alternative splicing is implicated in the malignant pathogenesis, where 
Brown, et al.19 and Keimpema, et al.20 have documented that alternatively spliced transcripts of FOXP1 are over-
expressed in the ABC subclass of DLBCL. Subtype specific ratios of NOTCH3 +/−exon 16 transcripts were 
observed for BAGS subtypes, suggesting specific splice regulation of NOTCH3 that could affect the function 
of NOTCH3 in different cell types depending on their degree of differentiation. The biological effect of exon 16 
skipping and the cell specific NOTCH3 +/−exon 16 transcript interplay is unknown, yet we know that exon 16 
encodes three EGF-like domains in the extracellular domain possibly affecting the protein-ligand interaction in 
a cell specific manner.
To evaluate the prognostic biomarker potential of the NOTCH3 −exon 16 transcript, R-CHOP treated 
patients were divided into two groups of high and low expression level and analysed for association with clinical 
outcome. NOTCH3 −exon 16 transcript expression exhibited prognostic potential in GCB classified patients, 
indicating that GCB patients with low expression display inferior OS. Although, clinical outcome is a result of the 
entire R-CHOP regimen, GCB classified patients with low expression levels of the NOTCH3 −exon 16 transcript 
was predicted to be vincristine resistant, which could potentially affect the survival outcome since vincristine is a 
cornerstone for efficacy of the R-CHOP regimen. Notably, no association with OS was observed when investigat-
ing the overall cohort or when restricting to ABC classified patients, supporting that altered NOTCH3 −exon 16 
transcript expression has a different impact depending on molecular subtypes of DLBCL. However, only a trend 
was observed within the GCB subclass, most likely due to the relative small sample size of our cohort. Therefore, 
more studies using a larger independent patient cohort are required to confirm the impact of the NOTCH3 −
exon 16 transcript on OS of GCB DLBCL patients.
In conclusion, we can experimentally confirm that quantification of alternative splicing events at exon level 
can be used to discriminate molecular subtypes of DLBCL. Evidence support that deregulated NOTCH signalling 
is a pathogenic driver in different haematological cancers23–25,27, however, most studies focus on NOTCH1 and 
NOTCH2 at DNA level. Here we document that the alternative splicing event in NOTCH3 mRNA show potential 
as biomarker for differentiating molecular subtypes of DLBCL. Specifically, when restricted to the GCB classified 
patients, NOTCH3 −exon 16 transcript expression demonstrates potential as a prognostic and predictive bio-
marker since patients with low expression of NOTCH3 −exon 16 transcript tend to have an adverse OS and be 
more resistant towards vincristine. This pilot study indicates that altered alternative splicing contributes to the 
pathogenesis of DLBCL depending on the molecular subtypes and may be promising as prognostic and predictive 
biomarker.
Materials and Methods
Patients. A retrospective cohort of optimal cutting temperature (OCT) compound embedded tissue biopsies 
collected at Aalborg University Hospital consisted of 75 de novo DLBCL patients. Tumor samples from DLBCL 
patients were collected at time of diagnosis in agreement with the RetroGen research protocol, reviewed and 
approved by the health ethic committee of the North Denmark Region (Approval jr. no. N-2014009) allowing 
exemption from the requirement of informed consent according to Sections 3 to 5 in Danish Act on Research 
Ethics Review of Health Research Projects. Informed consent was waived since this notifiable database research 
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project did not involve any health risks and under the given conditions could not otherwise put a strain on the trial 
subject. Additionally, it would be impossible or disproportionately difficult to obtain informed consent or proxy 
consent, respectively, due to archival samples going back as far as 1990 and that several patients have died since col-
lection. Diagnostic assessment of biopsies were performed by experienced hematopathologists. Of the 75 patients, 
60 patients were treated in accordance to the standard protocols of R-CHOP-like regimens (R-CHOP cohort) and 
none were treated with stem cell transplantation. Patient characteristics are summarized in Table 1. Lymph nodes 
from healthy donors (n = 6) were collected in accordance with the research protocol (MSCNET, N-20080062MCH) 
accepted by the local ethic committee of North Denmark Region. Mononuclear cells from healthy tonsils (n = 6) 
were sorted using multiparametric fluorescence-activated cell sorting (FACS) with 8 different surface markers 
obtaining B-cell subsets of naive, centroblast, centrocyte, memory, and plasma blast as previously described40.
RNA isolation. Total RNA was extracted using a combined protocol of TRIzol reagent (Invitrogen, Paisley, 
UK) and mirVana miRNA Isolation Kit (Ambion/ThermoFisher Scientific, Grand Island, NY) as previously 
described8. RNA concentration and integrity was determined using the Nanodrop ND-1000 spectrophotometer 
(ThermoFisher Scientific, Wilmington, DE, USA) and the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa 
Clara, CA), respectively.
Gene and exon expression profiling. Gene expression profiling of DLBCL patients (n = 75) was per-
formed using Affymetrix GeneChip HG-U133 Plus 2.0 arrays (Affymetrix, Santa Clara, CA) according to manu-
facturer’s instructions. In parallel, RNA from 37 of the DLBCL patients and 30 healthy sorted B-cell subsets from 
tonsil tissue were labelled and hybridized to Affymetrix GeneChip HuEx. 1.0 ST arrays (Affymetrix), as described 
by the manufacturer. CEL files were deposited at the NCBI GEO repository (HG-U133 Plus 2.0: GSE110376, 
HuEx 1.0 ST: GSE110548) and comply with MIAME requirements.
Droplet digital PCR. First-stranded cDNA was synthesized from 500 ng total RNA using SuperScript III 
First-Strand Synthesis SuperMix assay (Invitrogen) according to manufacturer’s instruction. Transcript expres-
sion of NOTCH3 with or without (+/−) exon 16 were quantified in DLBCL patients (n = 75) and healthy 
lymph node controls (n = 6) using QX200 ddPCR (Bio-Rad, Hercules, CA, USA). In brief, 5 µL of 12.5 ng/µL 
RNA-equivalent cDNA and 1 µL 900 nM primers/250 nM probe of each NOTCH3 +exon 16 (Hs00166432_m1) 
and NOTCH3 −exon 16 (APMFWV3) TaqMan assays (ThermoFisher Scientific) were mix with 11 µL of ddPCR 
Supermix for Probes (2x) (Bio-Rad). Nuclease-free water was added giving a total reaction mix volume of 22 µL. 
The +exon 16 assay amplifying NOTCH3 exon 16–17 has a VIC reporter, while the −exon 16 assay amplifying 
the 15–17 exon junction has a FAM reporter. Droplets were generated using Droplet Generation Oil for Probes 
(Bio-Rad) and 20 µL reaction mix, transferred to a 96-well PCR plate, and an endpoint PCR run was performed 
using GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA, USA) with the following program: 95 °C 
for 5 minutes, 40 cycles of 94 °C for 30 seconds, and 60 °C for 1 minutes, followed by 1 cycle of 98 °C for 10 min-
utes and cooling to 4 °C. Fluorescence of droplets were determined using the QX200 Droplet reader (Bio-Rad) 
and data analysed using the QuantaSoft software (Bio-Rad). Only samples with >12,000 droplets were accepted 
for analysis. The limit of detection was based on obtaining ≥2 droplets per primer/probe set. The amount of 
RNA-equivalent cDNA added to each reaction was used in the calculation of NOTCH3 +/−exon 16 transcript 
expressions quantified as copies/µg. The limit of detection was defined as 44 copies/µg RNA-equivalent cDNA. 
Since several isoforms of NOTCH3 transcripts are described41,42 with poor concordance of exact exon composi-
tion, expression of NOTCH3 −exon 16 was used alone or as ratios of NOTCH3 +exon 16, omitting normaliza-
tions to expression of exons positioned distant to the exact exon/region of interest.
Statistical analysis. Prior to statistical analyses, all array based gene expression data were background cor-
rected and normalized using the Robust Multichip Average (RMA) algorithm43. DLBCL patients were analysed 
by HG-U133 Plus 2.0 array in order to calculate subclass assignment probabilities of ABC/GCB, BAGS, and REGS 
using already published algorithms7–9. All DLBCL subtypes with n < 5 were excluded in the statistical analyses, 
and UC classified patients were excluded in the association analysis with ABC/GCB subclasses. The 37 patients 
analysed by HuEx. 1.0 ST arrays were used in identification of alternative splice variants between subclasses using 
the asANOVA function implemented in Partek Genomics Suite version 6.6. Lists containing genes with an alter-
native splice false discovery rate (FDR) corrected p < 0.05 were obtained for each classification system and the 
top 50 candidate genes were visually inspected. The mean gene expression of the candidate gene, NOTCH3, in 
DLBCL and healthy B-cells subsets were determined by extraction of hybridization-specific NOTCH3 HuEx. 1.0 
probes (3853114–3853174) and subsequently, association between NOTCH3 gene expression and BAGS subtypes 
were investigated using unpaired t-test.
Subtype (ABC/GCB, BAGS, and REGS vincristine) specific NOTCH3 −exon 16 transcript expression pat-
terns and association with healthy lymph node controls were analysed performing unpaired t-tests using ddPCR 
NOTCH3 −exon 16 expression data. To evaluate subtype specific expression variation of NOTCH3 +/−exon 16 
transcripts, Person’s correlation analysis was performed for each BAGS subtype, separately. The hypothesis of van-
ishing Person’s correlation coefficients were tested by Fishers-r-to-z transformation. The variation was assessed 
by the number of data points outside the 95% confidence interval bands of the linear regression curve. The slope 
of the fitted regression line was used to explain the ratio of NOTCH3 +/−exon 16 transcripts. Survival analysis 
was performed overall and according to ABC and GCB subclasses in the R-CHOP treated cohort (n = 60) using 
the Kaplan-Meier method and log-rank test statistics of survival probabilities. Overall survival (OS) was defined 
as the date of diagnosis to the date of death from any cause. Patients were divided into two equally large groups 
based on a median split of NOTCH3 −exon 16 transcript expression. All statistical analyses were performed using 
Graphpad Prism version 7.0, where all tests were two-tailed and p < 0.05 was considered statistically significant.
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